Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02502786 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02502786 · ClinicalTrials.gov record · last posted 2026-08-05

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Name: Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma — clinical trial record (NCT02502786)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorMemorial Sloan Kettering Cancer Center

Started2015-07

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.

Protocol amendment history 2 changes detected by DataLookout

2026-08-06

Primary completion pushed: 2026-07 → 2027-07

2026-08-06

Completion pushed: 2026-07 → 2027-07

Trial Details

NCT Number	NCT02502786
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: Children's Hospital Los Angeles, M.D. Anderson Cancer Center, Y-mAbs Therapeutics
Conditions	Recurrent Osteosarcoma
Enrollment	46 participants
Start Date	2015-07
Primary Completion	2027-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-05